A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)

Details 詳細情報について

• CRID

  1360572092464778752

• DOI

  10.1016/j.cllc.2020.09.023

• ISSN

  15257304

• Web Site

  https://api.elsevier.com/content/article/PII:S1525730420303053?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1525730420303053?httpAccept=text/plain

• Data Source

  • Crossref
  • KAKEN